Farms.com Home   News

Cigi, Cereals Canada Moving Closer Towards Amalgamation

The Canadian International Grains Institute (Cigi) and Cereals Canada are moving closer towards becoming an amalgamated organization.
 
Cereals Canada President Cam Dahl had an update on the process.
 
"There's been significant work on developing what governance might look like and what the by-laws might look like," he explained. "We're at a point now where those draft documents will be taken to members of both organizations for approval. We're looking at those votes to be happening in mid-April. If that's approved then the amalgamation itself is a go and we'll move ahead."
 
Dahl says merger talks have been going on for about four years.
 
He notes while there would be some cost savings involved, that was not the main reason behind the move.
 
"The principle drivers really are that improving in collaboration along the value chain, improvements in the effectiveness of the organization, and just doing a better job of supporting the industry and supporting our customers."
Click here to see more...

Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.